The COVID-19 and Cancer Consortium: NCI Administrative Supplement to P30 Cancer Center Support Grant (CCSG)

项目摘要 COVID-19是由SARS-coV-2病毒引起的疾病，现已影响近1亿人 全球有近200万人死亡。癌症患者在这方面有独特的风险特征， 流行病许多患者，特别是那些积极接受治疗的患者， 医疗保健系统。这可能包括提供者访问，静脉切开术，成像，社会工作和 财务咨询和输液室访问抗癌治疗和支持性护理， 就像输血一样。尽管为减少病毒在这些共享空间的传播做出了巨大努力， 患者暴露于COVID-19的风险增加。此外，大多数癌症患者 通过抗癌药物的骨髓毒性作用而免疫受损， 药物，如类固醇，和/或癌症本身;和超过60岁，把他们在 是COVID-19相关发病率和死亡率风险最高的类别。最后， 在几种癌症中，重要的合并症可以显著升高，例如慢性癌症， 肺癌中的阻塞性肺病或结肠直肠癌中的炎性肠病， 进一步加剧了它们对这种新病原体的脆弱性。 由于严重缺乏对极端脆弱性的了解和关注，COVID-19和 癌症联盟（CCC 19）于2020年3月成立，以了解新型病毒如何 影响癌症患者。虽然这一国家努力开始有机，主要是通过社会 媒体，会员人数迅速增长到450多名医疗保健专业人员和患者 代表美国、加拿大和墨西哥超过125个机构和组织的倡导者。 包括在这个成员是大多数的NCI指定的综合癌症 中心，NCI指定的癌症中心和大型社区实践网络，许多 这些都是NCORP网站。该联盟的主要目标是收集前瞻性的，颗粒状的， 统一组织的信息，以帮助生成翻译科学的假设，并武装 尽可能快地为癌症患者提供最完整的数据资源 感染了新冠病毒截至2021年1月，CCC 19已收集超过8000例病例报告， 高分析质量，并已在The Lancet，Cancer Discovery，Cancer 细胞和自然癌症。 作为联合体的研究协调中心，我们建立和传播最好的 治理、数据收集和数据传播的实践。我们负责主数据注册， 进行数据清理、质量保证和中央数据分析，并将与参与者合作 选择建立镜像本地数据库的机构。

Project Summary COVID-19, the disease caused by the SARS-coV-2 virus, has now affected nearly 100 million people globally, with nearly 2 million deaths. Patients with cancer have a unique risk profile in this pandemic. Many patients, especially those actively on treatment, have high levels of contact with the health care system. This can include provider visits, phlebotomy, imaging, social work and financial consultations, and infusion room visits for anti-cancer therapy and supportive care such as blood transfusions. Despite heroic efforts to reduce viral transmission in these shared spaces, patients are at an increased risk for COVID-19 exposure. Additionally, most cancer patients are immunocompromised through the marrow toxic effects of anti-cancer drugs, supportive medications such as steroids, and/or the cancer itself; and over 60 years of age, putting them in the highest-risk category for COVID-19-related morbidity and mortality. Finally, incidences of important comorbidities can be considerably elevated in several cancers, such as chronic obstructive pulmonary disease in lung cancer or inflammatory bowel disease in colorectal cancer, further exacerbating their vulnerability to this novel pathogen. Given an acute lack of knowledge and concern for extreme vulnerability, the COVID-19 and Cancer Consortium (CCC19) was formed in March 2020 to understand how the novel virus affects cancer patients. While this national effort began organically, primarily through social media, membership has quickly grown to over 450 healthcare professionals and patient advocates representing over 125 institutions and organizations in the US, Canada, and Mexico. Included in this membership are the majority of the NCI-designated Comprehensive Cancer Centers, NCI-Designated Cancer Centers and large networks of community practices, many of which are NCORP sites. The driving goal of the consortium is to collect prospective, granular, uniformly organized information to help generate hypotheses for translational science, and to arm treating providers with the most complete data resource as rapidly as possible on cancer patients infected with COVID-19. As of January 2021, CCC19 has collected over 8000 case reports of high analytical quality, and has published initial results in The Lancet, Cancer Discovery, Cancer Cell, and Nature Cancer. As the Research Coordinating Center for the consortium, we establish and propagate best practices for governance, data collection, and data dissemination. We host the main data registry, conduct data cleaning, quality assurance, and central data analysis, and will work with participant institutions who choose to set up mirrored local databases.